Treatment duration in part 1 phase 1b.
PD, tumor
DISEASE PROGRESSION, TUMOR, DISEASE, SOFT TISSUE SARCOMA, MALIGNANT PLEURAL MESOTHELIOMA
Selected tumor types in part 1 phase 1b evaluated included soft tissue sarcoma in arm 1, malignant pleural mesothelioma in arm 2, selected tumor types in basket arm 3 and arm 4. BOR, best objective response; CR, complete response; NA, not applicable; PR, partial response; PD, progressive disease; Q3W, once every 3 weeks; Q6W, once every 6 weeks; SD, stable disease.In part 2a, no objective responses were observed. Three patients (42.9%) in the nofazinlimab 300-mg Q4W/regorafenib 80-mg group and one patient (14.3%) in the nofazinlimab 300-mg Q4W/regorafenib 120-mg group achieved the best overall response of stable disease. Overall median PFS was 1.8 months (95% CI: 1.7–3.4), and 6- and 12-month PFS rates were both 9.4%. A total of six patients (42.9%) died, all due to disease progression.